<DOC>
	<DOCNO>NCT01208831</DOCNO>
	<brief_summary>The purpose study determine Maximum Tolerated Dose ( MTD ) recommend phase II dose LDE225 administer orally two adult patient group East Asian ( i.e. , Japanese Chinese/Taiwanese ) advance solid tumor progress despite standard therapy standard therapy exist .</brief_summary>
	<brief_title>An East Asian Study LDE225</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<criteria>confirm diagnosis advance solid tumor ( include medulloblastoma basal cell carcinoma ) blood work criterion patient history brain tumor ( except recurrent medulloblastoma ) brain metastasis positive HIV , hepatitis B C impair intestinal function impair heart function pregnant breastfeeding woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Advanced tumor</keyword>
	<keyword>hedgehog</keyword>
	<keyword>smoothen inhibitor</keyword>
</DOC>